QNTM Stock Risk & Deep Value Analysis
Quantum Biopharma Ltd
DVR Score
out of 10
What You Need to Know About QNTM Stock
We analyzed Quantum Biopharma Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran QNTM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
QNTM Risk Analysis & Red Flags
What Could Go Wrong
The most immediate risk is **financial liquidity**; with only $9.8 million in combined cash and digital assets as of March 31, 2026, and an estimated cash runway only until July 2027, Quantum Biopharma faces a significant capital raise requirement of potentially tens of millions of dollars to fund its Lucid-MS Phase 2 trial. Failure to secure this funding on favorable terms, or at all, would severely jeopardize its clinical development plans and potentially force a fire sale of assets, leading to substantial shareholder dilution or even insolvency.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Widening Net Loss: Q1 2026 net loss of US$13.56 million, widened by 58.1% YoY from US$8.58 million in Q1 2025, with no offsetting revenue.
- ⚠
Limited Cash Runway: Only US$9.8 million in combined cash, cash equivalents and digital assets as of March 31, 2026, with an estimated runway to only July 2027, indicating imminent need for substantial dilutive financing for its ~$30M-$50M Phase 2 trials.
- ⚠
Revenue Opacity: 'N/A' reported for revenue in Q1 2026 earnings, signaling lack of current income from operations.
- ⚠
Single Analyst Coverage: Reliance on a single analyst with an extremely optimistic price target (CAD 61.95), indicating low institutional confidence and broad market skepticism.
- ⚠
Dual Business Focus: Simultaneous pursuit of a high-risk, long-cycle biotech drug (Lucid-MS) and a nascent consumer product ('unbuzzd') could diffuse management's focus and capital efficiency.
Upcoming Risk Events
- 📅
Lucid-MS Phase 2 Trial Failure (Q1 2027 onwards): Negative or inconclusive results from the Phase 2 trial for Lucid-MS, leading to discontinuation of the program and potentially an 80%+ stock price decline.
- 📅
Inability to Secure Funding (Mid-2027): Failure to raise sufficient capital (e.g., $30M-$50M) to fund Lucid-MS Phase 2 beyond the estimated July 2027 cash runway, leading to significant dilution or pipeline halt.
- 📅
'unbuzzd' Commercial Failure (Q4 2026 onwards): Lack of market adoption or poor sales performance during the initial 'unbuzzd' rollout in South Florida and Texas, invalidating the consumer product diversification strategy and eliminating a potential revenue source.
When to Reconsider
- 🚪
Exit if combined cash, cash equivalents and digital assets (excluding significant unrealized crypto gains) drop below US$5 million.
- 🚪
Sell if Lucid-MS Phase 2 trial initiation is delayed beyond Q3 2026 without clear and compelling regulatory or operational justification.
- 🚪
Exit if any announced dilutive financing package reduces existing shareholder value by more than 30% through excessive share issuance or unfavorable terms.
- 🚪
Sell if 'unbuzzd' fails to achieve at least $1 million in gross sales within its initial South Florida and Texas rollout by Q4 2026, signaling poor market adoption.
Unlock QNTM Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Lucid-MS successfully completes its Phase 2 trial with compelling efficacy and safety data by late 2027 and 'unbuzzd' achieves annual royalty revenue of $5-10M by 2028 from its commercial rollout, then QNTM's market cap could re-rate from its current $50M to $500M-$700M, implying a 10x-14x return. This is bullish because the market currently assigns minimal value to the pipeline given its early stage, lack of current revenue, and the company's limited financial transparency, despite recent operational progress and reduced cash burn signaling improved efficiency.
Is QNTM Stock Undervalued?
Unlock the full AI analysis for QNTM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
QNTM Price Targets & Strategy
12-Month Target
$25.00
Bull Case
$45.00
Bear Case
$3.00
Valuation Basis
Derived from a projected early Phase 2 success for Lucid-MS and initial commercial traction for 'unbuzzd' contributing modest revenue/royalties, implying a speculative market capitalization of approximately $180M (based on ~7.2M estimated shares outstanding, assuming current market cap $0.05B / $7 per share = ~7.14M shares).
Entry Strategy
Dollar-cost average between $5.00-$8.00, targeting dips near current support levels, acknowledging extreme volatility and speculative nature.
Exit Strategy
Take 50% profit at $20, with a stop-loss at $5.00 to protect capital in this high-risk scenario.
Portfolio Allocation
2-5% for aggressive risk tolerance only, as a highly speculative satellite position.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is QNTM Financially Healthy?
Valuation
P/E Ratio
-0.84
Price/Book
20.90
Profitability
Operating Margin
-5052.26%
Net Margin
-9078.87%
Return on Equity
-417.59%
Revenue Growth
236.06%
EPS
$-8.72
Balance Sheet
Current Ratio
2.28
Quick Ratio
2.22
Debt/Equity
0.02
Other
Beta (Volatility)
4.36
Does QNTM Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
1 Identified
The company's nascent moat primarily relies on its intellectual property (IP) for Lucid-MS and 'unbuzzd'. However, this IP is extremely early-stage; Lucid-MS has not yet entered Phase 2, and 'unbuzzd' is just beginning commercialization. Without successful clinical trial outcomes leading to regulatory approval for Lucid-MS, or significant market adoption and patent protection for 'unbuzzd', the durability of any competitive advantage is very low and highly uncertain.
Moat Erosion Risks
- •Clinical Trial Failure: If Lucid-MS fails its Phase 2 trial, its core biotech IP becomes worthless, effectively eliminating any potential moat in CNS.
- •Competitive Landscape: Existing large pharmaceutical companies with approved MS therapies and robust R&D pipelines could develop superior or similar treatments, eroding any potential first-mover or efficacy advantage.
- •Commercialization Challenges: 'unbuzzd' could fail to gain market traction, or competitors could develop similar products or workarounds to Quantum's IP, limiting royalty streams.
QNTM Competitive Moat Analysis
Sign up to see competitive advantages
QNTM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While highly speculative biotechs can garner bullish retail interest, the lack of specific real-time social data suggests a neutral stance, with sentiment likely highly volatile based on news.
Institutional Sentiment
Negative. Despite a single 'Buy' rating with a high target, the very low institutional ownership (19 owners, 104,782 shares) indicates widespread institutional skepticism and minimal conviction.
Insider Activity (Form 4)
No Form 4 insider transactions were provided in the search results within the last 90 days. CEO/CFO buying or selling was not verified from the supplied sources.
Options Flow
Normal options activity. No specific unusual options activity or put/call ratio skew was indicated in the provided research.
Earnings Intelligence
Next Earnings
Estimated late August 2026 (for Q2 2026 results)
Surprise Probability
Medium (Highly sensitive to cash burn rate and any unexpected revenue from 'unbuzzd' or other sources, but continued net loss is expected)
Historical Earnings Pattern
Insufficient historical earnings data provided to establish a pattern, but given its early stage and lack of revenue, market reaction will likely be highly sensitive to pipeline updates and cash runway.
Key Metrics to Watch
Competitive Position
Top Competitor
Biogen (BIIB)
Market Share Trend
Losing (Currently has no market share in approved MS therapies; actively developing a drug that will enter a crowded market dominated by established players).
Valuation vs Peers
QNTM is pre-revenue and pre-profit, making traditional valuation multiples (P/E, EV/EBITDA, P/S) incomparable to established, revenue-generating biotech peers like Biogen. It trades at an extreme speculative premium based on potential future pipeline success, not current fundamentals.
Competitive Advantages
- •Proprietary IP: Potential differentiated mechanism of action for Lucid-MS and unique formulation for 'unbuzzd' (pending clinical/commercial validation).
- •Strategic Partnerships: Collaborations with Massachusetts General Hospital for imaging biomarkers and Allucent for CRO services could accelerate development and validation.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive QNTM Stock Higher?
Near-Term (0-6 months)
- •Lucid-MS Phase 2 Trial Initiation (Q2/Q3 2026): Commencement of patient enrollment for the planned Phase 2 trial following IND filing, validating pipeline progress.
- •Massachusetts General Hospital PET Imaging Study Full Results (Q3/Q4 2026): Publication of full results from the collaborative imaging study, aiming to validate improved biomarker precision for Lucid-MS. Potential to differentiate Lucid-MS from competitors.
- •'unbuzzd' South Florida/Texas Initial Sales Data (Q3 2026): Early commercial traction or specific sales milestones from licensee Unbuzzd Wellness Inc.'s rollout, indicating initial market acceptance and potential royalty generation.
Medium-Term (6-18 months)
- •Lucid-MS Phase 2 Initial Data Readout (Q1/Q2 2027): Interim or initial safety and efficacy data from the Phase 2 trial. Positive data could be a major re-rating event, potentially justifying a significant increase in market cap.
- •'unbuzzd' National Expansion Plans (H2 2027): Announcement of expansion beyond initial regions (South Florida/Texas), driven by early success, significantly increasing royalty revenue potential for Quantum BioPharma.
- •Resolution of CIBC/RBC Lawsuit (2027): Favorable resolution or settlement in the stock manipulation lawsuit, potentially leading to a cash inflow or removing a significant overhang on investor sentiment.
Long-Term (18+ months)
- •Lucid-MS Phase 3 Trial Initiation (2028+): Progression to a pivotal Phase 3 trial for Lucid-MS, positioning the drug closer to market and establishing Quantum BioPharma as a serious player in CNS therapeutics, leading to potential multi-billion dollar valuation.
- •Lucid-MS Regulatory Approval and Commercialization (2029+): FDA approval and subsequent commercial launch or licensing of Lucid-MS, establishing a durable revenue stream and validating the core biopharma strategy.
- •Sustained 'unbuzzd' Royalty Generation ($25M+ annual royalties by 2028): Consistent and growing royalty payments from 'unbuzzd', providing a non-dilutive funding source for future R&D or shareholder returns.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for QNTM?
- ✓
Watch Lucid-MS Phase 2 trial enrollment rates and any announced interim data readouts, as these are critical de-risking milestones.
- ✓
Monitor quarterly operating cash burn – a sustained increase above $2M/quarter without significant revenue growth would signal escalating financial risk.
- ✓
Track 'unbuzzd' quarterly royalty revenue and expansion announcements, with an initial target of $1M+ in Q3/Q4 2026 to validate commercial potential.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Quantum Biopharma Ltd Makes Money
Quantum BioPharma Ltd. is a clinical-stage biopharmaceutical company primarily focused on developing novel therapies for central nervous system (CNS) disorders, with its lead candidate, Lucid-MS, targeting Multiple Sclerosis and currently preparing for Phase 2 trials. Additionally, the company diversifies its asset portfolio by holding a significant ownership stake and royalty stream in 'unbuzzd', a consumer product designed to reduce blood alcohol content and increase alertness, which is beginning its commercial rollout. Quantum aims to generate revenue through the eventual success, commercialization, or licensing of its drug candidates, supplemented by recurring royalty payments from the 'unbuzzd' consumer wellness product.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Quantum Biopharma Ltd (QNTM)?
As of May 20, 2026, Quantum Biopharma Ltd has a DVR Score of 4.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Quantum Biopharma Ltd?
Quantum Biopharma Ltd's market capitalization is approximately $54.1M..
What is the risk level for QNTM stock?
Our analysis rates Quantum Biopharma Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of QNTM?
Quantum Biopharma Ltd currently has a price-to-earnings (P/E) ratio of -0.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Quantum Biopharma Ltd's revenue growing?
Quantum Biopharma Ltd has reported revenue growth of 236.1%. The company is showing strong top-line momentum.
Is QNTM stock profitable?
Quantum Biopharma Ltd has a profit margin of -9078.9%. The company is currently unprofitable.
How often is the QNTM DVR analysis updated?
Our AI-powered analysis of Quantum Biopharma Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for QNTM (Quantum Biopharma Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.